Advertisement
BIOA vs NBIX
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIOA is a Buy and NBIX is a Buy.
BIOA's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for BIOA turned positive on October 20, 2026. Looking at past instances where BIOA's MACD turned positive, the stock continued to rise in 16 of 18 cases over the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BIOA's RSI Indicator exited the oversold zone, 4 of 8 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 50%.
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on BIOA as a result. In 33 of 40 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
Following a +8.24% 3-day Advance, the price is estimated to grow further. Considering data from situations where BIOA advanced for three days, in 98 of 121 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
BIOA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 21 of 24 cases where BIOA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIOA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for BIOA entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 25 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.654) is normal, around the industry mean (6.379). P/E Ratio (-2.234) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (29.762) is also within normal values, averaging (183.387).
The Tickeron Price Growth Rating for this company is 83 (best 1 - 100 worst), indicating slightly worse than average price growth. BIOA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 94 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIOA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
NBIX in upward trend: price rose above 50-day moving average on November 03, 2026
NBIX moved above its 50-day moving average on November 03, 2026 date and that indicates a change from a downward trend to an upward trend. In 35 of 44 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 80%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on NBIX as a result. In 62 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 71%.
The Moving Average Convergence Divergence (MACD) for NBIX just turned positive on October 20, 2026. Looking at past instances where NBIX's MACD turned positive, the stock continued to rise in 32 of 53 cases over the following month. The odds of a continued upward trend are 60%.
The 10-day moving average for NBIX crossed bullishly above the 50-day moving average on November 03, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 78%.
Following a +2.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where NBIX advanced for three days, in 224 of 314 cases, the price rose further within the following month. The odds of a continued upward trend are 71%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 13 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 50-day moving average for NBIX moved below the 200-day moving average on October 27, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NBIX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.
NBIX broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for NBIX entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. NBIX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 44 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 44 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock slightly better than average.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 61 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.531) is normal, around the industry mean (6.379). P/E Ratio (23.352) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.280) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (4.587) is also within normal values, averaging (183.387).
The Tickeron PE Growth Rating for this company is 82 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
BIOA | NBIX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 21 | 39 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 25 Undervalued | 61 Fair valued | |
PROFIT vs RISK RATING 1..100 | 94 | 44 | |
SMR RATING 1..100 | 96 | 44 | |
PRICE GROWTH RATING 1..100 | 83 | 43 | |
P/E GROWTH RATING 1..100 | 100 | 82 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BIOA's Valuation (25) in the Chemicals Specialty industry is somewhat better than the same rating for NBIX (61) in the Biotechnology industry. This means that BIOA’s stock grew somewhat faster than NBIX’s over the last 12 months.
NBIX's Profit vs Risk Rating (44) in the Biotechnology industry is somewhat better than the same rating for BIOA (94) in the Chemicals Specialty industry. This means that NBIX’s stock grew somewhat faster than BIOA’s over the last 12 months.
NBIX's SMR Rating (44) in the Biotechnology industry is somewhat better than the same rating for BIOA (96) in the Chemicals Specialty industry. This means that NBIX’s stock grew somewhat faster than BIOA’s over the last 12 months.
NBIX's Price Growth Rating (43) in the Biotechnology industry is somewhat better than the same rating for BIOA (83) in the Chemicals Specialty industry. This means that NBIX’s stock grew somewhat faster than BIOA’s over the last 12 months.
NBIX's P/E Growth Rating (82) in the Biotechnology industry is in the same range as BIOA (100) in the Chemicals Specialty industry. This means that NBIX’s stock grew similarly to BIOA’s over the last 12 months.
| BIOA | NBIX | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 50% | 2 days ago 55% |
| Stochastic ODDS (%) | 2 days ago 88% | 2 days ago 54% |
| Momentum ODDS (%) | 2 days ago 82% | 2 days ago 71% |
| MACD ODDS (%) | 2 days ago 89% | 2 days ago 60% |
| TrendWeek ODDS (%) | 2 days ago 80% | 2 days ago 70% |
| TrendMonth ODDS (%) | 2 days ago 82% | 2 days ago 73% |
| Advances ODDS (%) | 2 days ago 81% | 2 days ago 71% |
| Declines ODDS (%) | 6 days ago 82% | 10 days ago 55% |
| BollingerBands ODDS (%) | 2 days ago 65% | 2 days ago 72% |
| Aroon ODDS (%) | 2 days ago 86% | 2 days ago 67% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BIOA’s FA Score shows that 1 FA rating(s) are green while NBIX’s FA Score has 0 green FA rating(s).
- BIOA’s FA Score: 1 green, 4 red.
- NBIX’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BIOA’s TA Score shows that 5 TA indicator(s) are bullish while NBIX’s TA Score has 5 bullish TA indicator(s).
- BIOA’s TA Score: 5 bullish, 3 bearish.
- NBIX’s TA Score: 5 bullish, 6 bearish.
Price Growth
BIOA (@Pharmaceuticals: Generic) experienced а -3.02% price change this week, while NBIX (@Pharmaceuticals: Generic) price change was +2.60% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.20%. For the same industry, the average monthly price growth was -6.54%, and the average quarterly price growth was +10.31%.
Reported Earning Dates
NBIX is expected to report earnings on Feb 11, 2027.
Industries' Descriptions
@Pharmaceuticals: Generic (-0.20% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement
BIOA and
Correlation & Price change
A.I.dvisor indicates that over the last year, BIOA has been loosely correlated with UPC. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if BIOA jumps, then UPC could also see price increases.
| Ticker / NAME | Correlation To BIOA | 1D Price Change % | ||
|---|---|---|---|---|
| BIOA | 100% | +1.58% | ||
| UPC - BIOA | 43% Loosely correlated | -3.13% | ||
| NBIX - BIOA | 38% Loosely correlated | +0.17% | ||
| TKNO - BIOA | 26% Poorly correlated | +2.11% | ||
| HROW - BIOA | 23% Poorly correlated | +10.52% | ||
| TEVA - BIOA | 23% Poorly correlated | -1.33% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| DIVE | 28.47 | N/A | +0.01% |
| Dana Concentrated Dividend ETF (DIVE) | |||
| TCAF | 43.12 | -0.10 | -0.23% |
| T. Rowe Price Capital Appreciation Equity ETF (TCAF) | |||
| ENHU | 27.96 | -0.10 | -0.37% |
| iShares Enhanced Large Cap Core Active ETF (ENHU) | |||
| MQQQ | 197.86 | -2.67 | -1.33% |
| Tradr 2X Long Innovation 100 Monthly ETF (MQQQ) | |||
| LDP | 19.21 | -0.38 | -1.94% |
| Cohen & Steers Limited | |||